Literature DB >> 14598885

Selection of more aggressive variants of the gI101A human breast cancer cell line: a model for analyzing the metastatic phenotype of breast cancer.

Dina Chelouche Lev1, Galina Kiriakova, Janet E Price.   

Abstract

In vivo models utilizing orthotopic injection of tumor cells into nude mice have proven valuable for the study of metastasis. However, breast cancers are among the more difficult of human tumors to grow in immunodeficient mice, with a relatively low tumor take. Fewer still develop spontaneous metastases. The injection of GI101A breast cancer cells into the mammary fatpad (mfp) produced lung metastases in 25% of tumor-bearing mice. Selecting cells from the lung metastases and recycling in vivo resulted in the isolation of a series of variant cell lines. These cell lines were tested for tumorigenicity and metastasis in nude mice following mfp injection compared with the original cell line, and in vitro expression of factors associated with the metastatic phenotype measured. The in vivo selected cell lines were more aggressive, with higher tumor take, faster local growth rate and increased incidence (> or = 85%) and extent of lung metastasis. However, the metastasis-selected variants showed no increases in expression of the growth factor receptors EGFR or HER-2, and the pro-angiogenic factors VEGF-A and IL-8. Immunohistochemistry of mfp tumors revealed no differences in microvessel density (counting CD-31 positive structures) and cell proliferation (PCNA-positive cells) comparing the GI101A line with selected variants. No TUNEL-positive cells were detected in the tumors of the metastasis-derived variant, with a small number of cells undergoing apoptosis detected in sections of GI101A tumors. In vitro, the metastasis-derived variants were found to have a more robust expression of phosphorylated PKB/Akt, with or without EGF or serum stimulation, suggesting an association between Akt activation and metastatic ability. This new series of isogenic cell lines may be valuable for identifying molecular mechanisms involved in the metastatic progression of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14598885     DOI: 10.1023/a:1025837631179

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  40 in total

Review 1.  Recent developments in breast cancer therapy.

Authors:  G N Hortobagyi; M C Hung; A U Buzdar
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

Review 2.  Transgenic mouse models of human breast cancer.

Authors:  J N Hutchinson; W J Muller
Journal:  Oncogene       Date:  2000-12-11       Impact factor: 9.867

3.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

4.  Expression of vascular endothelial growth factor by human renal cancer cells enhances angiogenesis of primary tumors and production of ascites but not metastasis to the lungs in nude mice.

Authors:  H Kanayama; S Yano; S J Kim; S Ozawa; L M Ellis; I J Fidler
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

5.  ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.

Authors:  U Hermanto; C S Zong; L H Wang
Journal:  Oncogene       Date:  2001-11-08       Impact factor: 9.867

6.  Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions.

Authors:  J Sun; M E Hemler
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

7.  Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice.

Authors:  J E Price; A Polyzos; R D Zhang; L M Daniels
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

Review 8.  Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients.

Authors:  G Gasparini; F Pozza; A L Harris
Journal:  J Natl Cancer Inst       Date:  1993-08-04       Impact factor: 13.506

Review 9.  Cancer cell societies and tumor progression.

Authors:  G H Heppner
Journal:  Stem Cells       Date:  1993-05       Impact factor: 6.277

10.  Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma.

Authors:  Nanami Itoh; Shuho Semba; Masafumi Ito; Hiroaki Takeda; Sumio Kawata; Mitsunori Yamakawa
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

View more
  11 in total

1.  Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar.

Authors:  Lixia Guo; Dominic Fan; Fahao Zhang; Janet E Price; Ju-Seog Lee; Dario Marchetti; Isaiah J Fidler; Robert R Langley
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

Review 2.  Strategies for the discovery and development of therapies for metastatic breast cancer.

Authors:  Bedrich L Eckhardt; Prudence A Francis; Belinda S Parker; Robin L Anderson
Journal:  Nat Rev Drug Discov       Date:  2012-06-01       Impact factor: 84.694

3.  Preclinical Breast Cancer Models to Investigate Metabolic Priming by Methionine Restriction.

Authors:  Elena Strekalova; Dmitry Malin; Harisha Rajanala; Vincent L Cryns
Journal:  Methods Mol Biol       Date:  2019

4.  Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity.

Authors:  Linda Hughes; Catherine Malone; Saranya Chumsri; Angelika M Burger; Susan McDonnell
Journal:  Clin Exp Metastasis       Date:  2008-04-02       Impact factor: 5.150

5.  Genomic signatures of breast cancer metastasis.

Authors:  V Urquidi; S Goodison
Journal:  Cytogenet Genome Res       Date:  2007       Impact factor: 1.636

6.  Repair and reconstruction of a resected tumor defect using a composite of tissue flap-nanotherapeutic-silk fibroin and chitosan scaffold.

Authors:  Vishal Gupta; Goo-Hyun Mun; Bina Choi; Abraham Aseh; Lopez Mildred; Anish Patel; Qixu Zhang; Janet E Price; David Chang; Geoffrey Robb; Anshu B Mathur
Journal:  Ann Biomed Eng       Date:  2011-06-25       Impact factor: 3.934

7.  ER-alpha-cDNA as part of a bicistronic transcript gives rise to high frequency, long term, receptor expressing cell clones.

Authors:  Michal Shenfeld; Yafit Hachmo; Moran Frenkel; Naomi Dafni; Michael Boettcher; Joerg D Hoheisel; Iris Dotan; Dan Canaani
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

8.  The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model.

Authors:  Hui Liu; Yukinari Kato; Stephanie A Erzinger; Galina M Kiriakova; Yongzhen Qian; Diane Palmieri; Patricia S Steeg; Janet E Price
Journal:  BMC Cancer       Date:  2012-12-07       Impact factor: 4.430

9.  Selection of metastatic breast cancer cells based on adaptability of their metabolic state.

Authors:  Balraj Singh; Karen Tai; Simran Madan; Milan R Raythatha; Amanda M Cady; Megan Braunlin; LaTashia R Irving; Ankur Bajaj; Anthony Lucci
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

10.  Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.

Authors:  Matthias Ilmer; Nachman Mazurek; Michael Z Gilcrease; James C Byrd; Wendy A Woodward; Thomas A Buchholz; Kim Acklin; Karen Ramirez; Margarete Hafley; Eckhard Alt; Jody Vykoukal; Robert S Bresalier
Journal:  Breast Cancer Res       Date:  2016-09-29       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.